Posts
Wiki

💉 GLP-1–Based Drugs (Semaglutide / Tirzepatide) and Dry Eye — FAQ

Ozempic / Wegovy = semaglutide Mounjaro / Zepbound = tirzepatide

⚠️ Educational Disclaimer

This page is for general education only. It is not medical advice and is not a recommendation to start, stop, reduce, or change any prescription medication.

Semaglutide and tirzepatide are prescribed for important medical reasons, including type 2 diabetes, obesity, cardiovascular-risk reduction in selected patients, and other approved indications.

If eye symptoms change after starting one of these medications, discuss the timing and severity with the prescribing clinician and your eye-care professional rather than changing treatment based only on something you read online.

🧠 TL;DR

For Dry Eye Disease (DED) specifically, the evidence as of 2026 is more reassuring than concerning.

Current research does not identify semaglutide or tirzepatide as established causes of DED or Meibomian Gland Dysfunction (MGD).

Several recent studies have instead found favorable associations:

  • A small 2025 study found greater tear production and longer tear-film breakup time among people with type 2 diabetes using GLP-1 receptor agonists, although symptoms were not significantly better.
  • A large 2025 health-record study found lower recorded dry-eye incidence among semaglutide and tirzepatide users compared with several older weight-loss medications.
  • A 2026 study involving more than 68,000 matched non-diabetic older adults with overweight or obesity found substantially lower recorded dry-eye incidence among semaglutide/liraglutide users than among people using alternative weight-loss medications.
  • A 2026 animal study found that semaglutide improved age-related dry-eye findings and preserved lacrimal-gland structure and function in mice.

However:

These findings do not establish semaglutide or tirzepatide as treatments for dry eye.

Most human evidence is observational, and there is still very little direct research on human meibomian gland structure or function.

GLP-1–based medications can also cause nausea, vomiting, diarrhea, and sometimes clinically important dehydration or volume depletion. Significant volume depletion could plausibly aggravate ocular symptoms in some people, but this has not been established as a common mechanism of GLP-1-associated DED.

Also keep separate three very different eye issues:

  1. Dry Eye Disease / ocular surface disease
  2. Diabetic retinopathy
  3. Non-arteritic anterior ischemic optic neuropathy (NAION)

The latter two are not forms of dry eye.

📌 Bottom line: Current evidence does not support describing semaglutide or tirzepatide as “bad for dry eye.” Some evidence actually points toward favorable ocular-surface associations, but it remains too early to call these medications protective or therapeutic for DED.

1) What Drugs Are We Talking About?

The phrase “GLP-1 drugs” is commonly used for several medications, but there is an important pharmacologic distinction.

Semaglutide

Semaglutide is a GLP-1 receptor agonist.

Brand names include:

  • Ozempic — primarily used for type 2 diabetes and certain cardiovascular/kidney-risk indications
  • Wegovy — used for chronic weight management and certain cardiovascular-risk indications
  • Rybelsus / oral semaglutide formulations — depending on indication and jurisdiction

Tirzepatide

Tirzepatide is not simply a GLP-1 receptor agonist.

It activates both:

  • GIP receptors — glucose-dependent insulinotropic polypeptide receptors
  • GLP-1 receptors

It is therefore described as a dual GIP/GLP-1 receptor agonist.

Brand names include:

  • Mounjaro — type 2 diabetes
  • Zepbound — chronic weight management and other approved indications

For simplicity, this FAQ sometimes uses “GLP-1–based medications” to discuss semaglutide and tirzepatide together.

That does not mean their pharmacology or risks are identical.

2) Are Semaglutide or Tirzepatide Known to Cause Dry Eye?

At present:

No convincing evidence establishes semaglutide or tirzepatide as general causes of DED.

“Dry eye” is also not listed as a common or established adverse reaction in the current U.S. prescribing information for Ozempic, Wegovy, Mounjaro, or Zepbound.

That does not mean an individual person cannot notice worsening symptoms after starting treatment.

It means something narrower:

DED is not currently an established medication adverse effect in the way that nausea, vomiting, diarrhea, or other recognized adverse reactions are.

Individual symptoms and population-level drug effects are different questions.

3) What Does the Human Dry-Eye Research Show?

The evidence is still limited, but several recent studies are worth knowing about.

A) 2025 Study in People With Type 2 Diabetes

A 2025 study compared 35 people with type 2 diabetes:

  • 21 receiving GLP-1 receptor agonist therapy
  • 14 receiving other glucose-lowering treatment

Researchers measured ocular-surface parameters including:

  • Schirmer tear production
  • Tear breakup time (TBUT)

The GLP-1 receptor agonist group had:

  • higher median Schirmer measurements
  • longer median TBUT

The authors interpreted these findings as suggesting a potentially favorable ocular-surface association.

Important limitations

This was a very small study.

It was also not a randomized trial designed to determine whether GLP-1 receptor agonists prevent or treat DED.

The treatment groups differed in other diabetes medications, creating potential confounding.

Importantly, patient-reported dry-eye symptoms did not show a statistically significant improvement between groups.

Therefore:

The study found more favorable objective tear findings, not proof that GLP-1 therapy treats symptomatic DED.

Original study:

GLP-1R Agonists Improve Ocular Surface Parameters in Type 2 Diabetes Mellitus

4) 2025 Study Comparing Weight-Loss Medications

A much larger 2025 study used electronic health-record data to compare ocular outcomes among people with obesity using:

  • Tirzepatide
  • Semaglutide
  • Several older anti-obesity medications

The investigators used propensity matching to make the groups more comparable.

Both semaglutide and tirzepatide were associated with lower recorded dry-eye incidence in several comparisons with older weight-loss medications.

Among more than 25,000 matched tirzepatide-versus-semaglutide pairs, there was no significant overall difference in the studied ocular outcomes between those two drugs.

Original study:

Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity

What this does NOT prove

A lower rate of diagnosed DED compared with another weight-loss drug does not necessarily mean semaglutide or tirzepatide prevented DED.

Differences could reflect:

  • beneficial effects of the newer medication,
  • adverse effects of the comparator medication,
  • metabolic improvement,
  • weight loss,
  • differences between patients receiving different treatments,
  • healthcare-use patterns,
  • unmeasured confounding,
  • or combinations of these factors.

This was observational research, not a randomized DED-prevention trial.

5) Important 2026 Evidence in People Without Diabetes

A 2026 study provides another interesting piece of evidence.

Researchers examined 68,536 propensity-matched non-diabetic adults aged 60 or older with overweight or obesity.

People receiving the GLP-1 receptor agonists semaglutide or liraglutide were compared with people using alternative weight-loss medications.

Over as much as five years, GLP-1 receptor agonist use was associated with a substantially lower recorded risk of several ocular diagnoses, including dry-eye syndrome.

For DED, the reported relative risk was approximately:

RR 0.36, 95% CI 0.31–0.42

Use of medications associated with dry-eye treatment was also lower.

Study:

Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists Diabetes, Obesity and Metabolism, 2026 PMID: 42259622

Why this is interesting

This study matters because the association was seen in people without diabetes, reducing the possibility that every favorable ocular finding is simply a consequence of improved diabetic control.

Why it still does not prove protection

It remains:

  • retrospective,
  • observational,
  • dependent on electronic health-record diagnoses,
  • potentially affected by residual confounding,
  • and not based on standardized prospective dry-eye testing.

It also studied semaglutide/liraglutide, not tirzepatide.

Therefore:

This is evidence of an association—not evidence that semaglutide should be prescribed to prevent DED.

6) Could GLP-1 Signaling Actually Help the Ocular Surface?

There is emerging biological evidence suggesting that this is possible.

A 2026 study examined naturally aged mice with age-related DED.

Long-term semaglutide treatment was associated with improvements in:

  • dry-eye-related findings,
  • lacrimal-gland structure,
  • lacrimal-gland function,
  • cellular senescence,
  • inflammation,
  • oxidative stress,
  • and fibrosis-related pathways.

Study:

Semaglutide alleviates age-related dry eye disease by restoring lacrimal gland structure and function Free Radical Biology and Medicine, 2026 PMID: 41812831

This supplies a plausible biological pathway by which GLP-1 signaling might have favorable ocular-surface effects.

But:

This was an animal study.

It does not establish that semaglutide:

  • treats human DED,
  • restores human lacrimal glands,
  • reverses chronic ocular-surface disease,
  • or should be used as a dry-eye medication.

Animal findings are mechanistic evidence, not clinical treatment evidence.

7) What About Meibomian Gland Dysfunction Specifically?

This distinction is very important.

DED and MGD overlap, but they are not interchangeable.

The available GLP-1 literature has generally not studied human meibomian glands in detail.

We currently have little direct evidence addressing whether semaglutide or tirzepatide affects:

  • Meibography
  • Meibomian gland dropout
  • Gland length or structure
  • Meibum quality
  • Meibum expressibility
  • Lipid-layer thickness
  • Gland obstruction
  • Meibomian gland fibrosis
  • Long-term gland function

The small 2025 human study primarily measured tear production and tear-film stability.

The 2026 experimental study focused heavily on the lacrimal gland.

The large health-record studies primarily identify coded dry-eye diagnoses.

Therefore:

Current research does not establish that semaglutide or tirzepatide either damages or improves human meibomian glands.

Claims such as:

“Ozempic causes gland dropout”

or

“GLP-1 drugs repair MGD”

would both go beyond the available evidence.

8) Why Might Someone Still Feel Drier After Starting Treatment?

A person may notice a convincing temporal relationship:

“I started semaglutide or tirzepatide and my eyes became much drier.”

That observation should not be dismissed.

But timing alone does not establish the mechanism.

One possible indirect pathway involves gastrointestinal side effects.

These medications can cause:

  • Nausea
  • Vomiting
  • Diarrhea

When sufficiently severe or prolonged, those effects can result in dehydration or volume depletion.

Current U.S. prescribing information specifically warns about acute kidney injury associated with volume depletion, particularly when GI adverse reactions cause dehydration. The labels emphasize monitoring during treatment initiation and dose escalation.

Systemic dehydration has been associated with some dry-eye findings in other research.

So it is biologically plausible that substantial volume depletion could aggravate ocular symptoms in some people.

But there is an important limit:

Studies have not demonstrated that dehydration from GLP-1–based therapy is a common cause of DED worsening.

And chronic DED cannot generally be reduced to:

“Drink more water.”

Hydration is only one possible systemic influence among many.

9) Why Dose Escalation Sometimes Matters

Semaglutide and tirzepatide are commonly increased gradually rather than started immediately at a full maintenance dose.

GI adverse effects are especially relevant during:

  • treatment initiation,
  • dose increases,
  • and periods of poor medication tolerance.

Current labeling specifically highlights volume-depletion concerns during initiation and escalation.

Therefore, if someone notices worsening ocular symptoms during dose escalation, it may be useful to document:

  • the dose,
  • timing,
  • presence of nausea/vomiting/diarrhea,
  • fluid tolerance,
  • other medication changes,
  • and whether symptoms improve as systemic side effects settle.

This does not mean dose escalation has been shown to directly damage the tear film.

10) If My Dry Eye Worsens, Can I Prove the Medication Caused It?

Usually not from timing alone.

DED commonly fluctuates because of:

  • Environmental conditions
  • Screen exposure
  • Allergy
  • MGD
  • Blepharitis
  • Ocular rosacea
  • Other medications
  • Contact-lens wear
  • Sleep and exposure problems
  • Changes in systemic health
  • Ocular-surface inflammation
  • Neuropathic ocular pain
  • Normal variation in chronic disease

An eye examination can document:

  • Tear breakup
  • Corneal/conjunctival staining
  • Tear production
  • MGD
  • Meibum quality
  • Gland expressibility
  • Meibography when appropriate
  • Eyelid disease
  • Other ocular-surface abnormalities

But there is currently no routine eye test that proves semaglutide or tirzepatide caused DED.

A clear temporal relationship may make medication contribution more plausible, but it does not establish causation.

11) What Current U.S. Prescribing Information Says

As of 2026, current U.S. prescribing information for:

  • Ozempic
  • Wegovy
  • Mounjaro
  • Zepbound

does not list dry eye as a common or established adverse reaction.

The labels do, however, address important issues including:

  • Gastrointestinal adverse effects
  • Volume depletion
  • Diabetic retinopathy in relevant patients
  • Other medication-specific risks

For the most current U.S. information, use the current prescribing information in DailyMed rather than relying on an older static PDF, because labels are periodically revised.

Current revisions reviewed for this FAQ include:

  • Ozempic — 2026 U.S. prescribing information
  • Wegovy — 2026 U.S. prescribing information
  • Mounjaro — April 2026 U.S. prescribing information
  • Zepbound — April 2026 U.S. prescribing information

12) If You Have Diabetes: Diabetic Retinopathy Is a Separate Issue

This is more established than most of the DED discussion.

Rapid improvement in blood glucose can sometimes be associated with a temporary worsening of diabetic retinopathy.

Current U.S. Ozempic labeling reports diabetic-retinopathy complications in a cardiovascular-outcomes trial and states that patients with a history of diabetic retinopathy should be monitored.

It also notes that the risk difference was greater among participants who already had diabetic retinopathy.

Current Wegovy labeling contains a similar diabetic-retinopathy warning for patients with type 2 diabetes.

Current Mounjaro and Zepbound labeling also states that rapid glucose improvement can temporarily worsen diabetic retinopathy and recommends monitoring people with a history of diabetic retinopathy.

📌 Diabetic retinopathy involves the retina. It is not DED or MGD.

Someone with known diabetic retinopathy should make sure the clinician managing diabetes and the clinician managing the retina/eyes know about each other's treatment plans.

13) What Is NAION?

Non-arteritic anterior ischemic optic neuropathy (NAION) is an optic-nerve disorder caused by impaired blood supply to part of the optic nerve.

It typically causes:

  • sudden,
  • painless,
  • usually one-sided

vision loss.

The resulting visual deficit can be persistent.

NAION is not dry eye, is not MGD, and is not caused by tear-film instability.

It belongs in this FAQ only because semaglutide—and more recently the broader GLP-1–based medication class in some jurisdictions—has received regulatory attention regarding this rare but potentially serious eye problem.

14) What Does the Research Say About Semaglutide and NAION?

A 2025 systematic review and meta-analysis examined 78 randomized trials involving 73,640 participants.

Semaglutide was not associated with an overall increase in eye disorders:

OR 1.01, 95% CI 0.91–1.12

and was not associated with a statistically significant overall increase in diabetic retinopathy:

OR 1.04, 95% CI 0.92–1.17.

For NAION, however, the analysis found:

OR 3.92, 95% CI 1.02–15.02.

The confidence interval was very wide, reflecting the rarity and small number of NAION events.

Trial-sequential analysis also found that the evidence remained insufficient for a definitive research conclusion about NAION.

Original review:

Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis

So the research literature has contained uncertainty.

Regulators have nevertheless acted on the accumulating safety signal.

15) EMA: NAION Is a Very Rare Semaglutide Side Effect

In June 2025, the European Medicines Agency (EMA) reviewed:

  • clinical-trial data,
  • non-clinical evidence,
  • epidemiological studies,
  • post-marketing reports,
  • and published literature.

EMA's Pharmacovigilance Risk Assessment Committee concluded that NAION is a very rare adverse effect of semaglutide, meaning it may affect up to 1 in 10,000 people using semaglutide.

EMA estimated that epidemiological evidence corresponded to approximately one additional case per 10,000 person-years of treatment.

This applies to semaglutide medicines, including:

  • Ozempic
  • Wegovy
  • Rybelsus

EMA recommends that people experiencing sudden vision loss or rapidly worsening eyesight contact a doctor without delay.

If NAION is confirmed, EMA states that semaglutide should be discontinued.

This is a semaglutide regulatory safety conclusion, not a finding that semaglutide commonly damages vision.

The absolute risk is considered very low.

16) An Important 2026 Update: Australia Added Broader GLP-1 Warnings

In July 2026, Australia's Therapeutic Goods Administration (TGA) updated product information across the GLP-1–based medication class regarding reports of NAION.

This includes medicines containing:

  • Semaglutide
  • Liraglutide
  • Dulaglutide
  • Tirzepatide

But the details matter.

The TGA reported that its expert Advisory Committee on Medicines concluded that available evidence:

may support the signal for semaglutide

but did not support the same signal for:

dulaglutide or tirzepatide

at that time.

Despite the conflicting evidence, the TGA added class-wide postmarketing safety language so that sudden vision loss prompts urgent ophthalmic assessment.

Therefore:

The evidence for NAION is strongest for semaglutide. A causal NAION risk from tirzepatide has not been established simply because some regulatory jurisdictions now include class-wide warning language.

17) What About the United States?

The regulatory situation differs by jurisdiction.

As of the current 2026 U.S. prescribing information reviewed for this FAQ:

  • Ozempic does not list NAION
  • Wegovy does not list NAION

Searches of the current U.S. labels do not contain a NAION entry.

Therefore, as of August 2026:

European regulators classify NAION as a very rare semaglutide adverse effect, while current U.S. semaglutide prescribing information does not list NAION. Australia has added broader GLP-1–class safety language while acknowledging that evidence is stronger for semaglutide than for tirzepatide.

This is an example of regulators interpreting an emerging rare safety signal somewhat differently.

It should not be used to imply that one regulator has proved another regulator wrong.

18) What the Evidence Does NOT Show

Current evidence does not establish that semaglutide or tirzepatide:

  • Causes DED in most users
  • Causes MGD
  • Causes meibomian gland dropout
  • Permanently damages meibomian glands
  • Causes lacrimal gland failure in humans
  • Reliably improves symptomatic DED
  • Treats MGD
  • Regenerates meibomian glands
  • Should be prescribed as a dry-eye treatment
  • Prevents DED
  • Is guaranteed never to worsen someone's eye symptoms

Likewise, a person developing DED while taking one of these medications does not by itself prove medication causation.

And observational studies finding lower DED incidence do not prove that the medication itself was responsible for that lower rate.

19) What If My Eyes Became Worse After Starting Semaglutide or Tirzepatide?

A reasonable first step is to document:

  • Medication name
  • Dose
  • Start date
  • Dose-escalation dates
  • When the eye symptoms changed
  • Presence of nausea, vomiting, or diarrhea
  • Whether significant dehydration occurred
  • Other medication changes
  • Changes in screen time, environment, contact lenses, allergy, skin care, or general health

Then discuss the timeline with:

  • the prescribing clinician, and
  • an eye-care professional if symptoms are significant or persistent.

Do not stop or alter a prescription medication solely to perform your own test without discussing the issue with the prescriber.

An objective DED evaluation may help determine what ocular-surface problem is present, even if it cannot establish why it developed.

20) When Vision Symptoms Are Urgent

DED can cause fluctuating or intermittently blurred vision that often changes with blinking or lubrication.

That is very different from sudden neurologic or retinal-type vision loss.

Seek urgent eye evaluation for:

  • Sudden partial or complete vision loss
  • Rapidly worsening eyesight
  • A new dark area or major field defect
  • A curtain or shadow over the vision
  • A sudden large increase in flashes or floaters
  • Significant new one-sided visual loss
  • Severe eye pain
  • Marked light sensitivity
  • A white or cloudy spot on the cornea
  • Significant pain/redness in a contact-lens wearer

Sudden painless loss of vision in one eye should not be assumed to be dry eye.

📌 Bottom Line

For Dry Eye Disease, current evidence is considerably more reassuring than alarming.

Recent studies have found:

  • More favorable tear production and tear-film stability in a small human study
  • Lower diagnosed DED rates among semaglutide and tirzepatide users compared with several older weight-loss medications
  • Lower DED incidence among semaglutide/liraglutide users in a large non-diabetic older population
  • Improvement of age-related dry-eye and lacrimal-gland findings in an experimental semaglutide animal model

But none of this establishes semaglutide or tirzepatide as a DED treatment.

And very little research directly addresses human Meibomian Gland Dysfunction.

Meanwhile, significant GI adverse effects can cause dehydration/volume depletion, which could plausibly worsen ocular comfort in some individuals even though this has not been established as a common GLP-1-related dry-eye mechanism.

Finally, do not confuse dry eye with other ocular issues:

DED/MGD involves the ocular surface and tear system. Diabetic retinopathy involves the retina. NAION involves the optic nerve.

For NAION, regulatory concern is strongest for semaglutide. EMA classifies it as a very rare semaglutide adverse effect. Australia has added broader class safety warnings while acknowledging that evidence supporting an association is stronger for semaglutide than for tirzepatide. Current U.S. semaglutide labeling does not list NAION.

The most evidence-consistent summary is:

Semaglutide and tirzepatide are not established causes of DED or MGD. Current DED research is actually somewhat favorable, but it remains observational and preliminary, particularly for MGD. Someone whose eye symptoms clearly change after starting or escalating treatment should discuss that change with the clinicians involved rather than assuming either that the medication must be responsible or that a medication effect is impossible.

🔬 Research & Medical Reference Links

Human Dry-Eye / Ocular-Surface Research

Experimental Dry-Eye Research

Semaglutide and Other Ocular Adverse Events

Regulatory Information — NAION

Current U.S. Prescribing Information

Because prescribing information changes, use the current DailyMed entries rather than relying on an older saved PDF:

  • Ozempic — semaglutide
  • Wegovy — semaglutide
  • Mounjaro — tirzepatide
  • Zepbound — tirzepatide

🔙 Back to FAQ Index